secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0000950170-25-096645
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics elects four Class I directors, ratifies auditor at 2025 annual meeting
--------------------------------------------------------------------------------

- Shareholders elected Dr. William Polvino, Scott Giberson, Erick Lucera, and Dr. Jay S. Skyler as Class I directors for three-year terms.
- Appointment of EisnerAmper LLP as independent auditor for fiscal year 2025 ratified with 6,374,363 votes for, 238,327 against.
- Quorum of 71.38% achieved; 6,633,125 shares present out of 9,291,697 outstanding.
- Broker non-votes of 2,154,677 on director elections; each director received over 4.3 million votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025096645/0000950170-25-096645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017025096645/sabs-20250717.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-096645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer